Lumenis Acquires Israeli-Based Pollogen Strengthening and Expanding Its Aesthetic Division

YOKNEAM, Israel, Nov. 2, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, announced today that the company has completed the acquisition of Pollogen Ltd.

"We are excited to welcome the Pollogen team into the Lumenis family," said Tzipi Ozer-Armon, CEO of Lumenis. "This transaction complements our aesthetic product portfolio and positions Lumenis well in the dynamic beauty market. The addition of Pollogen's extensive portfolio is key to continuing to provide tailored and innovative beauty solutions to all of our existing and future aesthetic customers."

Pollogen is an Israeli-based medical aesthetic company, a developer and manufacturer of advanced technologies with full-lines of clinically-proven, non-invasive anti-aging facial and body contouring treatment platforms for a spectrum of aesthetic applications. The product platforms include OxyGeneo(R), VoluDerm(TM), Hybrid Energy(TM), TriPollar(R), TriLipo(R) and TriFractional(TM). Pollogen will strengthen Lumenis' position in the beauty segment with its advanced solutions with a focus on radio-frequency technology.

"This transaction is a positive outcome for our shareholders, employees and customers," said Zion Azar, co-founder and Chairman of Pollogen.

"Over the past 10 years, Pollogen has built a leading position in the aesthetic beauty market based on a culture of innovation and pioneering research. We are thrilled to join the Lumenis team and further develop our products and presence in this rapidly developing market."

About Lumenis
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com.

About Pollogen
Pollogen believes in constantly challenging itself to create the most advanced, effective medical aesthetic technologies and solutions. The Company believes in thinking differently. Pollogen takes a customer-centric approach by making our products user-friendly, safe and convenient. The Company believes in finding ways to develop technologies that work with the body's natural mechanisms so beautiful results are generated from within.

Pollogen is the developer and manufacturer of five revolutionary technologies under the industry premier brand names OxyGeneo(R), VoluDerm(TM), Hybrid Energy(TM), TriPollar(R), TriLipo(R) and TriFractional(TM). We offer a full line of clinically-proven, safe and effective, non-invasive anti-aging facial and body contouring treatment platforms for a wide range of aesthetic applications. Pollogen provides solutions for professionals in over 60 countries, addressing the specific needs and dynamic changes unique to the ever-evolving aesthetic industry. http://www.pollogen.com

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.